Trial Profile
Control of COVID-19 Outbreaks in Long Term Care (CONTROL-COVID)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 24 Feb 2023
Price :
$35
*
At a glance
- Drugs Favipiravir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Acronyms CONTROL-COVID
- Sponsors Appili Therapeutics
- 17 Feb 2023 Status changed from active, no longer recruiting to discontinued.
- 11 Aug 2021 Planned End Date changed from 1 Mar 2021 to 1 Nov 2021.
- 11 Aug 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Nov 2021.